The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease
Abstract
Background: Cannabidiol (CBD) is one of the main components of Cannabis sativa and has anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on anxiety signs and symptoms in patients with Parkinson’s disease (PD). This study aimed to evaluate the impacts of acute CBD administration at a dose of 300 mg on anxiety measures and tremors induced by a Simulated Public Speaking Test (SPST) in individuals with PD. Methods: A randomised, double-blinded, placebo-controlled, crossover clinical trial was conducted. A total of 24 individuals with PD were included and underwent two experimental sessions within a 15-day interval. After taking CBD or a placebo, participants underwent the SPST. During the test, the following data were collected: heart rate, systemic blood pressure and tremor frequency and amplitude. In addition, the Visual Analog Mood Scales (VAMS) and Self-Statements during Public Speaking Scale were applied. Statistical analysis was performed by repeated-measures analysis of variance (ANOVA) while considering the drug, SPST phase and interactions between these variables. Results: There were statistically significant differences in the VAMS anxiety factor for the drug; CBD attenuated the anxiety experimentally induced by the SPST. Repeated-measures ANOVA showed significant differences in the drug for the variable related to tremor amplitude as recorded by the accelerometer. Conclusion: Acute CBD administration at a dose of 300 mg decreased anxiety in patients with PD, and there was also decreased tremor amplitude in an anxiogenic situation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · cited 3×
“The Hoehn and Yahr Scale was used to assess the stage and severity of PD.”
MethodInfluentialRecent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 3×
“…accordance with anxiolytic effects of CBD observed in studies using the SPST as an experimental model of anxiety in individuals with social anxiety (Bergamaschi et al., 2011b) and healthy volunteers (Linares et al., 2019; Zuardi et al., 1993), as well as during the Public Speaking in Real Life…”
BackgroundMethodSelf-citationAmygdala Microcircuits Controlling Learned Fear
Duvarci, S., & Pare, D. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.042 · Cited by 751
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 695
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01365 · Cited by 560
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 3×
“…accordance with anxiolytic effects of CBD observed in studies using the SPST as an experimental model of anxiety in individuals with social anxiety (Bergamaschi et al., 2011b) and healthy volunteers (Linares et al., 2019; Zuardi et al., 1993), as well as during the Public Speaking in Real Life…”
BackgroundMethodSelf-citation
Research works printed but not linked: 3
- Dissanayaka NN, 2016, Int Psychogeriatr, 1
- García-Arencibia M, 2009, J Neural Transm Suppl, 73, 269
- Zuardi AW, 1981, J Bras Psiquiatr, 31, 403
Cited by
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Moltke, J., & Hindocha, C. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00061-5 · Cited by 178
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited
Pirker, W., Katzenschlager, R., Hallett, M., & Poewe, W. H. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-225060 · Cited by 120
“CBDattenuatedanxietyandtremoramplitude,sug-gestingthatCBDmaybeabeneficialinPDpatients withanxiety-relatedtremor[106].”
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
Arnold, J. C., McCartney, D., Suraev, A. S., & McGregor, I. S. (2022) · Clinical and Translational Science · doi:10.1111/cts.13425 · Cited by 99
Metadata
- Authors
- de Faria, S. M., de Morais Fabrício, D., Tumas, V., Castro, P. C., Ponti, M. A., Hallak, J. E., Zuardi, A. W., Crippa, J. A. S., & Chagas, M. H. N.
- Affiliations
- Department of Gerontology, Federal University of São Carlos, São Carlos, Brazil
- Department of Psychology, Federal University of São Carlos, São Carlos, Brazil
- Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
- Universidade Federal de São Carlos (BR)
- Universidade de São Paulo (BR)
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01-07
- Volume
- 34
- Issue
- 2
- Pages
- 189-196
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2999274191
- Cited by
- 140
- References
- 52
- Citations by year
- 2026: 7 · 2025: 25 · 2024: 26 · 2023: 25 · 2022: 35 · 2021: 17 · 2020: 5
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (422208/2016-7)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2016/06561-2)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- cannabidiol, Parkinson's disease, anxiety, tremor, anxiolytic effects, tremor amplitude, placebo-controlled crossover trial
- MeSH terms
- Aged, Anxiety, Blood Pressure, Cannabidiol, Double-Blind Method, Female, Heart Rate, Humans, Male, Middle Aged, Parkinson Disease, Speech, Tremor, Treatment Outcome, Cross-Over Studies, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. https://app.cochat.ai/papers/10.1177/0269881119895536
- The paper
- de Faria, S. M., de Morais Fabrício, D., Tumas, V., Castro, P. C., Ponti, M. A., Hallak, J. E., Zuardi, A. W., Crippa, J. A. S., & Chagas, M. H. N. (2020). Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal of Psychopharmacology. https://doi.org/10.1177/0269881119895536
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.